Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931817 | 1.00 | LMNA (0.58) | LMNAALDH1A3ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL970318 | 0.85 | ALDH1A3 (0.57) | LMNAALDH1A3ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10694902 | 0.85 | ALDH1A1 (0.62) | LMNAALDH1A3ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5949941 | 0.84 | LMNA (0.78) | LMNAALDH1A1MAPTSMN1; SMN2POLB | |
| SCHEMBL9797252 | 0.83 | LMNA (0.60) | LMNAALDH1A1MAPTSMN1; SMN2HPGD | |
| SCHEMBL15335388 | 0.82 | ALDH1A3 (0.50) | LMNAALDH1A3ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL17070011 | 0.80 | ALDH1A1 (0.50) | LMNAALDH1A3ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL9470287 | 0.80 | ALDH1A3 (0.52) | LMNAALDH1A3ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5367181 | 0.80 | ALDH1A3 (0.61) | LMNAALDH1A3ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL945328 | 0.80 | ALDH1A1 (0.53) | LMNAALDH1A3ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170112-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | LUCY THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2025038783-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS OR CHRONIC HEART FAILURE | LUCY THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4479399-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Lucy Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023158725-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | LUCY THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158725-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | LUCY THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20210040268-A1 | MODIFIED POLYSILOXANE AND APPLICATION THEREOF | NANJING UNIVERSITY (CN) | 2021-02-11 | — | — | US | disclosed |
| US-20180133204-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | POXEL SA (FR) | 2018-05-17 | — | — | US | disclosed |
| US-9833445-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | DEUTERX, LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833445-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | DEUTERX, LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170049762-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | POXEL SA (FR) | 2017-02-23 | — | — | US | disclosed |
| EP-1994031-A1 | USE OF ADENOSINE A1 AND/OR DUAL A1/A2B AGONISTS FOR PRODUCTION OF MEDICAMENTS FOR TREATING DISEASES | Bayer HealthCare AG (DE) | 2008-11-26 | — | — | EP | disclosed |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2007101531-A1 | USE OF ADENOSINE A1 AND/OR DUAL A1/A2B AGONISTS FOR PRODUCTION OF MEDICAMENTS FOR TREATING DISEASES | BAYER HEALTHCARE AG (DE) | 2007-09-13 | — | — | WO | disclosed |
| EP-1812430-A1 | SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF | Bayer HealthCare AG (DE) | 2007-08-01 | — | — | EP | disclosed |
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1687250-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | Takasago International Corporation (JP) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006027142-A1 | SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-03-16 | — | — | WO | disclosed |
| WO-2005051882-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | PAH, TNNT2, VHL | LMNA 597/4885ALDH1A3 1202/4885ALDH1A1 739/4885 |
| US-20250170112-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ADORA2A, ADORA1, PDE7A | LMNA 1690/4885ALDH1A3 520/4885ALDH1A1 1355/4885 |
| US-20180133204-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SLC5A2, PPARD, DPP4 | LMNA 3037/4885ALDH1A3 1967/4885ALDH1A1 1258/4885 |
| US-20170049762-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SLC5A2, PPARD, DPP4 | LMNA 3037/4885ALDH1A3 1967/4885ALDH1A1 1258/4885 |
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | ALDH1A2, ALDH1A3, GRHPR | LMNA 1420/4885ALDH1A3 2/4885ALDH1A1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.